Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:LBPH

Longboard Pharmaceuticals (LBPH) Stock Price, News & Analysis

Longboard Pharmaceuticals logo

About Longboard Pharmaceuticals Stock (NASDAQ:LBPH)

Advanced Chart

Key Stats

Today's Range
$59.98
$59.98
50-Day Range
$59.50
$59.98
52-Week Range
$15.64
$60.03
Volume
N/A
Average Volume
1.06 million shs
Market Capitalization
$2.34 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$63.00
Consensus Rating
Hold

Company Overview

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

Receive LBPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Longboard Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LBPH Stock News Headlines

H Lundbeck A/S (HLUNAC.XD)
H. Lundbeck A/S (HLUN-A.CO)
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
See More Headlines

LBPH Stock Analysis - Frequently Asked Questions

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) released its quarterly earnings results on Thursday, August, 1st. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by $0.10.
Read the conference call transcript
.

Longboard Pharmaceuticals (LBPH) raised $75 million in an IPO on Friday, March 12th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share. Citigroup, Evercore ISI, Guggenheim Securities and Cantor acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Longboard Pharmaceuticals investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Visa (V) and Home Depot (HD).

Company Calendar

Last Earnings
8/01/2024
Today
5/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LBPH
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$63.00
High Stock Price Target
$90.00
Low Stock Price Target
$44.00
Potential Upside/Downside
+5.0%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-54,420,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.67 per share
Price / Book
35.92

Miscellaneous

Free Float
37,234,000
Market Cap
$2.34 billion
Optionable
Optionable
Beta
1.00
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:LBPH) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners